## Table of Contents

### Breaking Advances
- **3995** Highlights from Recent Cancer Literature

### Reviews
- **3997** The Stress Kinase p38α as a Target for Cancer Therapy
  Ana Igea and Angel R. Nebreda
- **4003** Cell-of-Origin of Cancer versus Cancer Stem Cells: Assays and Interpretations
  Kiera Rycaj and Dean G. Tang
- **4012** The MYC–WDR5 Nexus and Cancer
  Lance R. Thomas, Audra M. Foshage, April M. Weissmiller, and William P. Tansey

### Perspectives
- **4016** Recommendations for Benchmarking Preclinical Studies of Nanomedicines
  Charlene M. Davidczyk, Luisa M. Russell, and Peter C. Searson
- **4021** Inferring the Origin of Metastases from Cancer Phylogenies
  Woo Suk Hong, Max Shpak, and Jeffrey P. Townsend

### Priority Report
- **4026** Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer
  **Précis:** This first transcriptome sequencing of castration-resistant prostate cancer reports the discovery of a long noncoding RNA that may offer a druggable target in ERG+ prostate cancers.

### Clinical Studies
- **4032** High-Resolution Rapid Diagnostic Imaging of Whole Prostate Biopsies Using Video-Rate Fluorescence Structured Illumination Microscopy
  Mei Wang, Hillary Z. Kimberl, Andrew B. Sholl, David B. Tullman, Katherine N. Elfer, Tyler C. Schlichenmeyer, Benjamin R. Lee, Michelle Lacey, and J. Quincy Brown
  **Précis:** This study describes the utility of a novel microscopic method for high-throughput, nondestructive pathologic imaging and diagnosis of malignant biopsy tissue, with the potential to replace current techniques and assess tissue quality and diagnosis at the point of acquisition.

### Integrated Systems and Technologies
- **4042** A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis
  Elisabeth Bens, Sandra Rebouissou, Claudine Chaoukiya, Andrei Zinovyev, François Radvanj, and Laurence Calzone
  **Précis:** This multidisciplinary study explains the basis for mutual exclusivity and co-occurring genetic alterations in bladder cancer through the use of a mathematical model that provides context and temporal orders for these alteration patterns.
- **4053** Implication of the Autologous Immune System in BCR–ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib
  Geoffrey D. Clapp, Thomas Lepoutre, Raouf El Cheikh, Samuel Bernard, Jérémy Ruby, Hélène Labussière-Wallet, Franck E. Nicolini, and Doron Levy
  **Précis:** Variations in BCR-ABL transcripts during imatinib therapy may represent a signature of the patient’s individual autologous immune response, as modeled by a mathematical algorithm in this study that may help design patient-specific schedules for TKI combination therapy.
MICROENVIRONMENT AND IMMUNOLOGY

4063 Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages
Casey Frankenberger, Daniel Rabe, Russell Bainer, Devipriya Sankara-Sharma, Kiran Chada, Thomas Krausz, Yoav Gilad, Lev Becker, and Marsha Rich Rosner

Précis: These findings suggest that ‘triple-negative’ breast cancer patients may benefit greatly from therapeutics that target tumor-associated macrophages, addressing a clinical need for effective targeted therapies in this setting.

4074 CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer
Tatiana A. Karakasheva, Todd J. Waldron, Evgeniy Eruslanov, Sang-Bae Kim, Ju-Seog Lee, Shaun O’Brien, Philip D. Hicks, Devraj Basu, Sunil Singhal, Fabio Malavasi, and Anil K. Rustgi

Précis: This report highlights CD38 as a new marker of highly immunosuppressive MDSC as well as a candidate therapeutic target, addressing a long-standing need to more fully define functional biomarkers in this key myeloid cell population mediating immune escape.

4086 Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer
Frank Kuhnert, Guoying Chen, Sandra Coetzee, Nithya Thambi, Carlos Hickey, Jing Shan, Pavel Kovalenko, Irene Noguera-Troise, Eric Smith, Jeanette Fairhurst, Julian Andreev, Jessica R. Kirshner, Nicholas Papadopoulos, and Gavin Thurston

Précis: These findings establish a therapeutic rationale for antibody-based targeting of a Notch ligand in ovarian cancer, as an antiangiogenic strategy that is particularly potent in combination with VEGF blockade.

4097 Anti-CD20 Therapy Acts via FcRIIIA to Diminish Responsiveness of Human Natural Killer Cells
Cristina Capuano, Maddalena Romanelli, Chiara Pighi, Giuseppe Cimino, Angela Rago, Rosa Molfetta, Rossella Paolini, Angela Santoni, and Ricciarda Galandrini

Précis: These findings define a novel mechanism of immune exhaustion caused by rituximab or related CD20 mAb in human natural killer cells, with potentially negative implications for patients treated with these therapies.

CARCINOGENESIS

MOLECULAR AND CELLULAR PATHOBIOLOGY

4109 Carbonic Anhydrase Activity Monitored In Vivo by Hyperpolarized 13C-Magnetic Resonance Spectroscopy Demonstrates Its Importance for pH Regulation in Tumors

Précis: An enzyme that is highly elevated in hypoxic conditions and that engenders metastatic progression is found to have a critical role for lowering extracellular pH, with potential implications as a therapeutic target in hypoxic conditions when tumors are typically resistant to therapy.

4119 The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis
Garcilaso Riesco-Eizaguirre, Leon Wort-Lamas, Javier Perales-Patón, Ana Sastre-Perona, Lara P. Fernandez, and Pilar Santisteban

Précis: These findings reveal that a microRNA network underlies thyroid cell differentiation and function, with important implications for overcoming treatment-refractory metastatic thyroid cancer.

4131 Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma

Précis: These findings show that HGF/MET signaling enhances cancer hallmarks in adrenocortical carcinoma, where it may also contribute to drug resistance, with implications for the use of MET inhibitors as a clinical treatment strategy in this disease.

4143 HTLV-1 bZIP Factor RNA and Protein Impart Distinct Functions on T-cell Proliferation and Survival
Yuichi Mitobe, Jun-ichirou Yasunaga, Rie Funuta, and Masao Matsuoka

Précis: This study elucidates a central function in the human cancer virus HTLV-1 that enables it to efficiently promote leukemogenesis.
Enhanced Chemokine Receptor Recycling and Impaired SIP1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia
Laura Patrussi, Nagaja Capitani, Veronica Martini, Marco Pizzi, Valentina Trimarco, Federica Frezzato, Filippo Marino, Gianpietro Semenzato, Livio Trentin, and Cosima T. Baldari
Précis: These findings show how cell surface recycling dynamics controlled by endocytic processes account for high surface levels of CXCRI4 and CCR7 in chronic B cell tumors, and how the targeted drug ibrutinib impacts this balance in achieving therapeutic responses.

Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer
Ruud H. Wijdeman, Baoxu Pang, Sabina Y. van der Zanden, Xiaohang Qiao, Vincent Blomen, Marlous Hoogstraat, Esther H. Wessels, Lennert Janssen, Lodewyk Wessels, Thijn R. Brummelkamp, and Jacques Neefjes
Précis: These findings describe the characterization of three novel mechanisms underlying resistance to the commonly used anticancer drugs doxorubicin and etoposide, with implications for stratifying cancer patients into the most effective treatment regimens.

Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma
Tadaaki Yamada, Joseph M. Amann, Koji Fukuda, Shinji Takeuchi, Naoya Fujita, Hisanori Uehara, Shotaro Iwakiri, Kazumi Itoi, Konstantin Shilo, Seiji Yano, and David P. Carbone
Précis: These findings suggest an important role for the Akt1/CREB axis in the pathogenesis of diffuse malignant mesothelioma, a deadly lung cancer, and also offer a preclinical rationale to target Akt1 in this disease setting.

Feed-Forward Reciprocal Activation of PAFR and STAT3 Regulates Epithelial–Mesenchymal Transition in Non–Small Cell Lung Cancer
Jie Chen, Tian Lan, Weimin Zhang, Liija Dong, Nan Kang, Shumin Zhang, Ming Fu, Bing Liu, Kangtai Liu, and Qimin Zhan
Précis: These results elucidate a powerful mechanism of self-reinforcing malignant character in lung adenocarcinoma, driven by a tripartite G protein-coupled receptor that may offer an appealing therapeutic target.

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
Francis W. Hunter, Richard J. Young, Zvi Shalev, Ravi N. Vellanki, Jingli Wang, Yongchuan Gu, Naveen Joshi, Sneevsian Sreebhavan, Ilan Weinreb, David P. Goldstein, Jason Moffat, Troy Ketela, Kevin R. Brown, Marianne Koritzinsky, Benjamin Solomon, Danny Rischin, William R. Wilson, and Bradly G. Wouters
Précis: This study identifies a factor that appears to be critical for the response to a class of hypoxia-targeting drugs, with implications for improving the treatment of hypoxic solid tumors.
ABOUT THE COVER

Dll4-expressing endothelial cells activate Notch1 on adjacent ovarian tumor cells. Immunohistochemical staining for active Notch1 (nuclear Notch1 intracellular domain) and the tumor cell marker vimentin demonstrates Notch1 signaling activity in the tumor vasculature (elongated nuclei) and in vimentin-positive, tumor vessel-associated parenchymal cells. This pattern illustrates the important concept of juxtacrine signaling interactions between Dll4 expressed by endothelial cells and adjacent, Notch1-positive ovarian tumor cells. For details, see article by Kuhnert and colleagues on page 4086.